Mabpharm Limited reported unaudited consolidated earnings results for the six months ended June 30, 2021. For the period, the company reported revenue of RMB 81,246,000. Loss and total comprehensive expense for the period was RMB 145,161,000 against RMB 54,188,000 a year ago. Loss per share basic attributable to ordinary equity holders of the company was RMB 0.04 against RMB 0.01 a year ago.